ERBB2 and breast carcinoma: For instance, in a phase I/II trial of intrathecal trastuzumab for LM in human epidermal growth factor receptor 2 positive (HER2+) breast carcinoma (42) aimed at characterizing changes in CSF CTCs over time as a potential biomarker of treatment response.